Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.7M Buy
25,177
+7,554
+43% +$503K 0.01% 1266
2026
Q1
$1.11M Buy
+17,623
New +$1.23M 0.01% 1373
2025
Q4
Sell
-12,829
Closed -$863K 1249
2025
Q3
$863K Buy
12,829
+1,148
+10% +$90.8K 0.01% 1221
2025
Q2
$1.02M Buy
11,681
+3,235
+38% +$254K 0.01% 1060
2025
Q1
$577K Buy
8,446
+436
+5% +$35.6K 0.01% 1165
2024
Q4
$623K Buy
8,010
+2,163
+37% +$160K 0.01% 1102
2024
Q3
$392K Buy
5,847
+335
+6% +$27.5K 0.01% 1163
2024
Q2
$625K Sell
5,512
-6
-0.1% -$759 0.01% 992
2024
Q1
$765K Buy
5,518
+1,295
+31% +$163K 0.01% 972
2023
Q4
$524K Buy
4,223
+820
+24% +$83.8K 0.01% 978
2023
Q3
$318K Buy
3,403
+780
+30% +$87.9K 0.01% 1045
2023
Q2
$337K Buy
+2,623
New +$317K 0.01% 924
2022
Q1
Sell
-12,804
Closed -$1.72M 256
2021
Q4
$1.72M Buy
+12,804
New +$1.84M 0.19% 127
2020
Q4
Sell
-13,548
Closed -$1.4M 175
2020
Q3
$1.4M Sell
13,548
-380
-3% -$39.7K 0.44% 82
2020
Q2
$1.41M Buy
+13,928
New +$1.25M 0.55% 62
2019
Q2
Sell
-41,652
Closed -$1.24M 102
2019
Q1
$1.24M Buy
+41,652
New +$1.46M 0.44% 92

Other funds holding DXCM

Empowered Funds's DXCM Position: Q2 2026 in Review

Empowered Funds increased its DexCom (DXCM) stake by 43% in Q2 2026, buying an estimated $503K and bringing the position to 25,177 shares worth $1.7M. The position accounts for 0.01% of the portfolio, ranked #1266.

Empowered Funds first reported a position in DXCM in Q1 2019 and has held it in 16 quarters since. The position peaked at $1.72M in Q4 2021. 968 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Empowered Funds held 25,177 shares of DexCom worth $1.7M as of Q2 2026.
  • Empowered Funds bought 7,554 DexCom shares in Q2 2026, an estimated $503K.
  • DexCom made up 0.01% of Empowered Funds's portfolio in Q2 2026, its #1266 holding.
  • Empowered Funds first reported a position in DexCom in Q1 2019 and has held it in 16 quarters since.
  • Empowered Funds's DexCom position peaked at $1.72M in Q4 2021.
  • 968 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Empowered Funds's 13F filing for Q2 2026, filed 17 Aug 2026.